Hepatitis C Journal Articles

• The "Netflix Model" for Hepatitis C Virus Therapies This paper describes the development and implementation of a novel subscription-based pricing model for HCV therapeutics, the Payer License Agreement.
  Liver International, July 26, 2022
• Factors Associated With COVID-19 Severity in People With HIV Learn more about the risk factors associated with COVID-19 severity among people living with HIV.
  JAIDS: Journal of Acquired Immune Deficiency Syndromes, July 20, 2022
• Evaluating Effectiveness of Routine HBV and C Testing in an ED This study evaluated the real-world sustainability of an emergency department opt-out HCV and HBV testing program. Is opt-out ED testing practical in a large urban hospital setting?
  Journal of Viral Hepatitis, July 19, 2022
• HCV Eradication in HCC and Decreased Hepatic Functional Reserve Does DAA therapy after hepatocellular carcinoma treatment benefit patients with advanced-stage HCC or HCC with decompensated cirrhosis?
  Journal of Viral Hepatitis, July 12, 2022
• HCV Eradication Ameliorates the Prognosis of Advanced HCC According to this study, HCV eradication may not only improve liver function but also improve the prognosis of patients with HCV-related advanced HCC in patients treated with sorafenib.
  Journal of Viral Hepatitis, July 05, 2022
• Efficacy and Safety of DAA Therapy for HCV in Elderly Patients Is the efficacy of direct-acting antivirals, as measured by SVR, significantly different in patients 65 and older compared to younger patients?
  Journal of Viral Hepatitis, June 28, 2022
• Screening of Esophageal Varices in HCV+ Cirrhotic Patients This study aimed to evaluate the optimal type, frequency and length of surveillance of esophageal varices in HCV-positive cirrhotic patients who achieved SVR by direct-acting antivirals.
  Liver International, June 13, 2022
• Therapies for Managing Cirrhosis and its Complications This review outlines the currently available and emerging therapeutic options for the treatment of cirrhosis and its complications.
  Alimentary Pharmacology & Therapeutics, June 08, 2022
• Updated Histological Criteria of Autoimmune Hepatitis This consensus statement reviews the previous histological criteria of autoimmune hepatitis, and proposes updated criteria to be used for its diagnosis.
  Liver International, June 06, 2022
• Global Prevalence of Occult Hepatitis B A better understanding of the prevalence of occult HBV infection in the global population could lead to the development of better prevention and management strategies.
  Journal of Viral Hepatitis, May 30, 2022
• Association Between NAFLD and the Risk of Dementia The prevalence of both NAFLD and dementia is on the rise. Is there a link between the two?
  Liver International, May 30, 2022
• COVID-19 Impacts on Prevention and Care for HIV, Other STIs Restrictions imposed due to the COVID-19 pandemic have resulted in limited access to care and treatments. How have these delays impacted patients with HIV and other STIs?
  AIDS, May 27, 2022
• Genetic Factors in Sofosbuvir Treatment for Chronic HCV Are there patient-specific genetic factors that might help predict HCV patients likely to fail sofosbuvir treatment?
  Liver International, May 23, 2022
• Incidence and Mortality of HBV and HCV, Cirrhosis and HCC This article provides an update on the global incidence and mortality rates for these liver diseases. How have they changed in recent years?
  Journal of Viral Hepatitis, May 23, 2022
• Comorbidities and Co-Medications Among People With HIV How prevalent are comorbidities and the use of non-ART co-medications among people living with HIV?
  HIV Medicine, May 19, 2022
• Medicaid Restriction Removal Increased HCV Treatment Rates Access to treatment improved after Medicaid-imposed restrictions were removed, but more policy changes are needed to address remaining disparities.
  Journal of Viral Hepatitis, May 16, 2022
• Adherence to the DASH Diet and NAFLD Is the DASH (Dietary Approaches to Stop Hypertension) diet effective at lowering risk of NAFLD?
  Liver International, May 09, 2022
• HCV-Related Depression, Anxiety, and Cognitive Improvements Chronic HCV patients may realize neuropsychiatric and cognitive improvements after achieving sustained virological response with direct-acting antiviral agents.
  Journal of Viral Hepatitis, May 09, 2022
• Overt HE in Cirrhotic Patients With Acute Decompensation This study aimed to determine whether the occurrence of overt hepatic encephalopathy is an independent risk factor for de novo infection in patients with cirrhosis and acute decompensation.
  Alimentary Pharmacology & Therapeutics, April 27, 2022
• Incidence of HCV Related HCC in the Era of IFN-free Therapies This study examined trends over time of HCV-associated hepatocellular carcinoma. How has incidence changed since the introduction of IFN-free therapies?
  Liver International, April 25, 2022